- Clinical Trials
- April 2025
- 60 Pages
Global
From €1325EUR$1,500USD£1,132GBP
- Report
- April 2025
- 175 Pages
Global
From €3966EUR$4,490USD£3,387GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2208EUR$2,500USD£1,886GBP
- Report
- April 2025
- 200 Pages
Global
From €7021EUR$7,950USD£5,998GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1104EUR$1,250USD£943GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1104EUR$1,250USD£943GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1104EUR$1,250USD£943GBP
- Report
- August 2023
- 150 Pages
United States
From €3312EUR$3,750USD£2,829GBP
- Report
- May 2023
- 196 Pages
Global
From €2208EUR$2,500USD£1,886GBP
P-Selectin is a type of hematological drug used to treat a variety of conditions related to the blood, such as thrombosis, inflammation, and cancer. It is a type of cell adhesion molecule that binds to other cells, allowing them to stick together and form clots. P-Selectin is also involved in the process of leukocyte rolling, which is important for the immune system to respond to infection.
P-Selectin is used in a variety of treatments, including anticoagulants, anti-inflammatory drugs, and cancer therapies. It is also used in research to study the role of cell adhesion molecules in the development of diseases.
The P-Selectin market is highly competitive, with many companies offering products for different applications. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bristol-Myers Squibb. Other companies include AstraZeneca, GlaxoSmithKline, and Roche. Show Less Read more